First Manhattan’s Amicus Therapeutics FOLD Stock Holding History

First Manhattan’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-657	Closed	-$6K	–	1402
2020 Q1	$6K	Buy	+657	New	+$6.25K	﹤0.01%	1210
2018 Q3	–	Sell	-5,000	Closed	-$78K	–	1403
2018 Q2	$78K	Buy	+5,000	New	+$75.6K	﹤0.01%	864
2013 Q4	–	Sell	-153,300	Closed	-$355K	–	1379
2013 Q3	$355K	Hold	153,300	–	–	﹤0.01%	554
2013 Q2	$364K	Buy	+153,300	New	+$471K	﹤0.01%	551

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan's FOLD Position: Q2 2020 in Review

First Manhattan sold out of Amicus Therapeutics (FOLD) in Q2 2020, closing a stake of 657 shares — an estimated $6K sold.

First Manhattan first reported a position in FOLD in Q2 2013 and held it in 4 quarters. The position peaked at $364K in Q2 2013. 227 funds tracked by Wall St. Rank hold FOLD as of Q2 2020.

First Manhattan reported no remaining Amicus Therapeutics position as of Q2 2020 after selling out during the quarter.
First Manhattan sold 657 Amicus Therapeutics shares in Q2 2020, an estimated $6K.
First Manhattan first reported a position in Amicus Therapeutics in Q2 2013 and held it in 4 quarters.
First Manhattan's Amicus Therapeutics position peaked at $364K in Q2 2013.
227 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.